Perry C. Siatis - 28 Feb 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, GC AND SECRETARY
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis
Issuer symbol
ABBV
Transactions as of
28 Feb 2025
Net transactions value
-$7,435,909
Form type
4
Filing time
04 Mar 2025, 17:00:18 UTC
Previous filing
24 Feb 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Tax liability $1,613,507 -7,870 -35% $205.02 14,511 28 Feb 2025 Direct
transaction ABBV Common Stock, $0.01 par value Sale $558,223 -2,718 -19% $205.38 11,793 28 Feb 2025 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $1,407,289 -6,811 -58% $206.62 4,982 28 Feb 2025 Direct F2
transaction ABBV Common Stock, $0.01 par value Sale $75,210 -363 -7.3% $207.19 4,619 28 Feb 2025 Direct F3
transaction ABBV Common Stock, $0.01 par value Options Exercise $421,768 +2,918 +63% $144.54 7,537 03 Mar 2025 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1,094,470 +7,315 +97% $149.62 14,852 03 Mar 2025 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1,362,802 +7,775 +52% $175.28 22,627 03 Mar 2025 Direct
transaction ABBV Common Stock, $0.01 par value Sale $3,781,680 -18,008 -80% $210.00 4,619 03 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Disposed to Issuer $421,768 -2,918 -100% $144.54 0 03 Mar 2025 Common Stock 2,918 $144.54 Direct F4
transaction ABBV Option (Right to buy) Disposed to Issuer $1,094,470 -7,315 -50% $149.62 7,314 03 Mar 2025 Common Stock 7,315 $149.62 Direct F4
transaction ABBV Option (Right to buy) Disposed to Issuer $1,362,802 -7,775 -33% $175.28 15,549 03 Mar 2025 Common Stock 7,775 $175.28 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.99 to $205.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.01 to $207, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.12 to $207.37, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.